Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. 2018 update of the EULAR recommendations for the management of Behçet's syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Maja Skov Kragsnaes
  • Jens Kjeldsen
  • Hans Christian Horn
  • Heidi Lausten Munk
  • Finn Moeller Pedersen
  • Hanne Marie Holt
  • Jens Kristian Pedersen
  • Dorte Kinggaard Holm
  • Henning Glerup
  • Vibeke Andersen
  • Ulrich Fredberg
  • Karsten Kristiansen
  • Robin Christensen
  • Torkell Ellingsen
Vis graf over relationer

INTRODUCTION: An unbalanced intestinal microbiota may mediate activation of the inflammatory pathways seen in psoriatic arthritis (PsA). A randomised, placebo-controlled trial of faecal microbiota transplantation (FMT) infused into the small intestine of patients with PsA with active peripheral disease who are non-responsive to methotrexate (MTX) treatment will be conducted. The objective is to explore clinical aspects associated with FMT performed in patients with PsA.

METHODS AND ANALYSIS: This trial is a randomised, two-centre stratified, double-blind (patient, care provider and outcome assessor), placebo-controlled, parallel-group study. Eighty patients will be included and randomised (1:1) to either placebo (saline) or FMT provided from an anonymous healthy donor. Throughout the study, both groups will continue the weekly self-administered subcutaneous MTX treatment, remaining on the preinclusion dosage (15-25 mg/week). The clinical measures of psoriasis and PsA disease activity used include the Short (2-page) Health Assessment Questionnaire, the Dermatology Quality of Life Index, the Spondyloarthritis Research Consortium of Canada Enthesitis Index, the Psoriasis Area Severity Index, a dactylitis digit count, a swollen/tender joint count (66/68), plasma C reactive protein as well as visual analogue scales for pain, fatigue and patient and physician global assessments. The primary end point is the proportion of patients who experience treatment failure during the 6-month trial period. The number of adverse events will be registered throughout the study.

ETHICS AND DISSEMINATION: This is a proof-of-concept clinical trial and will be performed in agreement with Good Clinical Practice standards. Approvals have been obtained from the local Ethics Committee (DK-S-20150080) and the Danish Data Protection Agency (15/41684). The study has commenced in May 2017. Dissemination will be through presentations at national and international conferences and through publications in international peer-reviewed journal(s).

TRIAL REGISTRATION NUMBER: NCT03058900; Pre-results.

OriginalsprogEngelsk
TidsskriftBMJ Open
Vol/bind8
Tidsskriftsnummer4
Sider (fra-til)e019231
ISSN2044-6055
DOI
StatusUdgivet - 27 apr. 2018

ID: 54748518